Skip to main content
. 2018 Apr 30;15(6):5475–5480. doi: 10.3892/etm.2018.6109

Figure 1.

Figure 1.

Serum IL-10 levels in benign and malignant breast diseases. (A) IL-10 levels in healthy women (n=70) and patients with atypical hyperplasia (n=95), papilloma (n=85), fibroma (n=88) or ductal carcinoma (n=110). (B) Serum IL-10 levels in patients with different clinical stages of ductal carcinoma. (C) Serum IL-10 levels in patients with ductal carcinoma that were ER+ compared with those that were ER−. (D) Serum IL-10 levels in patients with ductal carcinoma that were PR+ compared with those that were PR−. (E) Serum IL-10 levels in patients with ductal carcinoma that were HER2+ positive compared with those that were HER2−. *P<0.05; **P<0.01 and ***P<0.0001. Data are representative of three different experiments and presented as the mean ± standard error of the mean. IL, interleukin; NS, not significant; ER, estrogen receptor; PR, progesterone receptor; HER2, Human epidermal growth factor receptor 2.